Global access to management of primary hyperoxaluria: a survey on behalf of OxalEurope, G&K Working Group of the ERA and ESPN
Lisa J. Deesker(Emma Kinderziekenhuis), Justine Bacchetta(Université Claude Bernard Lyon 1), Michiel J.S. Oosterveld(Emma Kinderziekenhuis), Neveen A. Soliman(Cairo University), Melvin Bonilla‐Félix(University of Puerto Rico, Medical Sciences Campus), John A. Sayer(Newcastle University), Lucile Figueres(Inserm), Pépé Mfutu Ekulu(University of Kinshasa), Sander F. Garrelfs(Emma Kinderziekenhuis), Michelle A. Baum(Boston Children's Hospital), Qian Shen(Sun Yat-sen University), Shabbir H. Moochhala(Université Claude Bernard Lyon 1), Reham Almardini(Al-Balqa Applied University), Jaap W. Groothoff(University of Amsterdam), Laila Oubram(Emma Kinderziekenhuis), Roman-Ulrich Müller(University of Cologne)
Cited by 9
Related Papers
Fluid Overload and Mortality in Children Receiving Continuous Renal Replacement Therapy: The Prospective Pediatric Continuous Renal Replacement Therapy Registry
|American Journal of Kidney Diseases|2009|690
A Single-Gene Cause in 29.5% of Cases of Steroid-Resistant Nephrotic Syndrome
|Journal of the American Society of Nephrology|2014|660
The centrosomal protein nephrocystin-6 is mutated in Joubert syndrome and activates transcription factor ATF4
|Nature Genetics|2006|573
Pediatric patients with multi-organ dysfunction syndrome receiving continuous renal replacement therapy
|Kidney International|2005|510
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
|New England Journal of Medicine|2021|505